OR-AIRSHIP
16.11.2023 15:01:37 CET | Business Wire | Press release
As organizations rush to adopt AI, a data-driven focus is foundational — not only to fuel better AI, but to avoid sacrificing long-term customer value for short-term gains. Nowhere is this more important than in mobile app experience, where value creation opportunities are 3-4X greater than anywhere else.
Today, mobile app experience company Airship introduced a host of enhancements to make continuous experimentation and optimization even easier.
From optimizing the performance of cross-channel customer journeys to refining messages, campaigns and no-code native app experiences, to testing app user experience and features themselves, all Airship experiments are now centralized in an Experimentation Hub. It’s a dashboard that anyone can use to create, launch and evaluate experiments and obtain a common understanding of the end-to-end experimentation and optimization strategy.
Holdout Experiments take A/B testing and control groups to a new level, allowing marketers to measure their impact on business goals by comparing audiences that receive marketing-led experiences versus those that don’t. Feature Flags enable teams to turn functionality on and off, run tests with control groups, activate short-term campaigns and make iterative experience enhancements before rolling them out to full audiences — all without the need for new code deployment or app store updates.
Airship has also centralized its visual reporting environment, providing real-time insights from all active experiments, as well as customer, channel and campaign data, into one place. A new App Health Reporting dashboard provides at-a-glance KPIs to help marketers and product owners understand app performance across the mobile app lifecycle.
Register to join two leading brand experts as they explore how continuous experimentation and optimization drives better results for businesses in a December 5 webinar.
Since the introduction of Airship’s no-code native App Experience Editor, businesses around the world have enabled non-technical teams to easily create, automate and adapt native app experiences for continuous onboarding and first-party and zero-party data collection. Numerous nominations for Airship’s annual customer awards program — The Altitude Awards — have documented their successes with agile creation and experimentation, including:
“Experimentation is fully integrated into Burger King France’s strategy, as we strive to deliver personalized, innovative experiences across all channels, from campaigns to product testing and new services,” said Valentin Pereira, CRM Project Manager. “Airship’s no-code native app experiences make it easy to go beyond messaging to optimize critical multiscreen app flows as well as important customer journeys and multi-channel campaigns. Results of initial app experience tests will have us repeating Airship Stories and videos at key moments in the customer journey — from welcoming new app users to launching major sales promotions.”
“Olio is fighting climate change by connecting people everywhere to give away rather than throw away, and share rather than shop, which makes our mobile app and notification opt-ins critical to facilitating rapid sharing and exchanges,” said Gareth Main, Chief Customer Officer at Olio. “Airship’s no-code native app experiences have enabled our entire team to quickly take action and experiment to improve users’ experiences, including recent tests that grew our notification opt-in rate by 24% while identifying a new approach we’ll take for future campaigns.”
“With more than 10 apps in total, we measure customer satisfaction daily. Previously, we used an HTML webview to deliver surveys to app users, which proved to be a distracting experience, resulting in low response rates,” said Laurent Claramonte, head of data analytics for Products and Mobile Apps, Orange France. “Since moving to Airship’s no-code native app experiences to quickly deploy, test and adapt onboarding flows, surveys and more, we now get as many customer survey responses in a day as we used to receive in a month.”
Winners of Airship’s Altitude Awards will be announced at Mobile Leaders Forum London later today.
“Customers’ first experiences with brands have an outsized impact on future value, especially when it comes to mobile app experiences where more than half decide whether to delete a new app in the first two uses,” said Brett Caine, CEO and president, Airship. “Brands need to recognize the limited window they have to make a compelling case for app customers to stick around. With Airship’s solution approach we are streamlining creation, experimentation and optimization, giving brands the keys to unlock agile optimization and more quickly achieve their business goals.”
About Airship
No one knows more, does more, or cares more than Airship when it comes to helping brands master mobile app experience (MAX).
From the beginning of apps, Airship powered the first commercial messages and then expanded its data-led approach to all re-engagement channels (mobile wallet, SMS, email), app UX experimentation, no-code native app experience creation and App Store Optimization (ASO).
Having powered trillions of mobile app interactions for thousands of global brands, Airship’s technology and deep industry expertise have enabled apps to become the digital center of customer experience, brand loyalty and monetization.
With the Airship App Experience Platform and Gummicube’s ASO technology and expertise, brands now have a complete set of solutions to optimize the entire mobile app customer journey – from the point of discovery to loyalty – driving greater value for everyone involved.
For more information, visit www.airship.com, read our blog or follow us on X (formerly Twitter), LinkedIn and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231116362912/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
